Researchers at St. Louis University, Washington University in St. Louis, and Fimbrion Therapeutics Inc. have identified ubiquinol-cytochrome C reductase cytochrome b subunit (qcrB) (Mycobacterium tuberculosis) inhibitors reported to be useful for the treatment of tuberculosis.